Nurix Therapeutics, Inc.
↗San Francisco, USA
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels. The company utilizes its proprietary DEL-AI (DNA-encoded library and artificial intelligence) discovery engine and deep expertise in E3 ligases to develop targeted protein degraders and degrader-antibody conjugates (DACs) for the treatment of cancer and autoimmune diseases.
Headquartered in San Francisco, California, Nurix is a publicly traded company (NASDAQ: NRIX) that has established significant strategic partnerships with major pharmaceutical companies, including Gilead Sciences, Sanofi, and Pfizer, to leverage its platform for drug discovery. The company's clinical pipeline includes candidates such as bexobrutideg (NX-5948), zelebrudomide (NX-2127), and NX-1607.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$50M-$100M
Founded:2009
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$482M (non-dilutive financing from partners)
Investors:Bain Capital Life Sciences, Third Rock Ventures, Fidelity Management & Research
STOCK
Exchange:NASDAQ
Ticker:NRIX
Market Cap:$1.53B
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 2 (Bexobrutideg/NX-5948)
Modalities:Small molecule, Targeted protein degradation, Degrader-antibody conjugates (DACs)
Active Trials:3
Trial Phases:Phase 1: 3 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Gilead Sciences (Drug discovery collaboration), Sanofi (Drug discovery collaboration), Pfizer (Drug discovery collaboration)
COMPETITION
Position:Emerging
Competitors:BeiGene, Arvinas, Kymera Therapeutics
LEADERSHIP
Key Executives:
Arthur T. Sands - CEO
Gwenn M. Hansen - Chief Scientific Officer
Paula O'Connor - Chief Medical Officer
Scientific Founders:Arthur Weiss, John Kuriyan, Michael Rape
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Nurix Therapeutics, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Nurix Therapeutics, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.